all 3 groups demonstrated statistically significant improvement in the hdrs-17 (primary outcome measure), 16-item quick inventory of depressive symptomatology-self report (qids-sr-16), and clinical global improvement-severity scale (cgi-s) (p < .05), but neither n-3 preparation separated from placebo (p > .05).